Compounded medications are not FDA-approved, are not reviewed for safety or effectiveness by the FDA before marketing, and may differ from FDA-approved drugs in formulation, manufacturing, and oversight
It is the low and slow approach to weight loss
In October 2006, the Endocrinologic and Metabolic Drugs FDA Advisory Committee recommended that the tamoxifen prescribing information be updated to indicate that patients who are slow-CYP2D6 metabolizers may be at increased risk for breast cancer recurrence
If the initial treatment plan is not producing the intended results, patients can request a follow-up assessment through the dashboard, and the provider can adjust the plan accordingly
The theory behind this is related to how quickly the medication is absorbed into the subcutaneous fat (the fat just under the skin) and how it then enters the bloodstream
The lateral oblique lumbar interbody fusion (OLIF) surgical approach was used (Fig